UPDATE : Monday, September 7, 2020
상단여백
Patients with ‘Invossa stigma’ struggle to get treatment, insurance by Jeong Sae-im 2019-06-26 13:22
Oscotech wins exception policy for continued R&D for new drugs by Jeong Sae-im 2019-06-25 14:11
‘Customized strategies needed for fast-changing Chinese drug regulation’ by Jeong Sae-im 2019-06-21 14:12
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting by Jeong Sae-im 2019-06-20 14:20
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’ by Jeong Sae-im 2019-06-18 14:43
라인
Korea can benchmark Philadelphia’s rise as ‘Cellicon Valley’: experts by Jeong Sae-im 2019-06-18 13:42
Korean biosimilars take on original drugs in Europe by Jeong Sae-im 2019-06-17 15:26
294 shareholders file suit against Kolon TissueGene for damage compensation by Jeong Sae-im 2019-06-14 10:51
‘Many drugs won Chinese approval without review suspension’ by Jeong Sae-im 2019-06-13 11:26
Daewoong’s botulinum toxin hits a snag in European approval by Jeong Sae-im 2019-06-12 16:50
라인
‘Medytox got review suspension in China only once’ by Jeong Sae-im 2019-06-11 10:50
CJ HealthCare to invest ₩100 billion in new IV fluid factory by Jeong Sae-im 2019-06-10 16:17
Medytox’ botulinum toxin may face approval delay in China by Jeong Sae-im 2019-06-10 13:55
Kolon TissueGene CEO resigns by Jeong Sae-im 2019-06-07 15:35
Pharma industry urges deregulation to develop new drug using AI by Jeong Sae-im 2019-06-05 11:53
라인
FDA OKs phase-1 trial for Yuhan’s investigational lung cancer drug by Jeong Sae-im 2019-06-04 14:21
Kolon’s minority shareholders demand over ₩25 billion in damage by Jeong Sae-im 2019-06-03 14:53
Invossa inventor sold Kolon shares at highest value by Jeong Sae-im 2019-06-03 14:52
Hanmi’s hypertension drug was effective in phase-4 study  by Jeong Sae-im 2019-05-31 16:05
Until when will Kolon keep lying about Invossa? by Jeong Sae-im 2019-05-31 14:59
여백
여백
여백
Back to Top